3 most recent filings and news items mentioning QURE. Updated every 60 seconds.
curl "https://api.brieftape.com/v1/tickers/QURE/news?limit=20"
Pull QURE filings straight into your trading bot, model, or app.
Get an API key — free tier: 10,000 calls/dayuniQure announced preliminary six-month data from its Phase I/IIa trial of AMT-260 for refractory mesial temporal lobe epilepsy, with three of six patients achieving 79-100% seizure reductions and no serious adverse events reported. The favorable safety profile and early biologic
View filing at SEC.gov →The FDA agreed that uniQure's 3-year Phase I/II data for AMT-130 can serve as the primary basis for accelerated approval of the gene therapy for Huntington's disease, with BLA submission expected in Q3 2026. This regulatory milestone significantly de-risks the pathway to market f
View filing at SEC.gov →7 Health Care Stocks With Whale Alerts In Today's Session
View filing at SEC.gov →